Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma

Immune-checkpoint inhibitor (ICI) efficacy in patients with non-small cell lung cancer (NSCLC) harboring molecular alterations remains poorly elucidated. This study was undertaken to determine ICI efficacy against epidermal growth-factor receptor (EGFR)/anaplastic lymphoma kinase (ALK)/c-ros oncogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bylicki, Olivier, Guisier, Florian, Monnet, Isabelle, Doubre, Hélène, Gervais, Radj, Janicot, Henri, Perol, Maurice, Fournel, Pierre, Lamy, Régine, Auliac, Jean-Bernard, Chouaid, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220079/
https://www.ncbi.nlm.nih.gov/pubmed/32011450
http://dx.doi.org/10.1097/MD.0000000000018726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220079/
https://www.ncbi.nlm.nih.gov/pubmed/32011450
http://dx.doi.org/10.1097/MD.0000000000018726

Ejemplares similares